The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open accessPublished version of a preprint
Abstract
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sensitivity to standard or investigational therapies. Overall, 37.1% (319/860) of patients received a matched therapy guided by their tumor molecular profile. Excluding alterations associated with standard-of-care therapy, 14.4% (69/478) received matched therapy, with a clinical benefit of 52%. Use of matched therapy was strongly influenced by the level of preexistent clinical evidence that the mutation identified predicts for drug response. Analysis of genes mutated significantly more often in tumors without known actionable mutations nominated STK11 and KEAP1 as possible targetable mitogenic drivers. Significance: An increasing number of therapies that target molecular alterations required for tumor maintenance and progression have demonstrated clinical activity in patients with lung adenocarcinoma. The data reported here suggest that broader, early testing for molecular alterations that have not yet been recognized as standard-of-care predictive biomarkers of drug response could accelerate the development of targeted agents for rare mutational events and could result in improved clinical outcomes. Cancer Discov; 7(6); 596–609. ©2017 AACR. See related commentary by Liu et al., p. 555. This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [21]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Somatic mutations in LKB1 and KEAP1 significantly co-occur with mutant KRAS and with each other in NSCLC15, 59, 63, 91.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Although EGFR –mutant tumors represent the prototypical oncogene-addicted LUAD subgroup that spearheaded adoption of the single-driver model, the overwhelming majority of EGFR-mutant lung tumors harbor one or more co-mutations, even when the analysis is limited to pre-defined sets of cancer-relevant genes within established panels (FoundationOne, Guardant360, MSK-IMPACT)15, 59, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- OncoKB.org, 2016, Precision Oncology Knowledge Base [Internet]
- Banno, 2016, : 10.1111/.12980, Sensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?, Cancer Sci · DOI
Cited by
Sorted by citations
Items 201–300 of 645
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer
Heylen, E., Verstraete, P., Aerschot, L. V., Geeraerts, S. L., Venken, T., Timcheva, K., Nittner, D., Verbeeck, J., Royaert, J., Gijbels, M. J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02216-y · Cited by 30
Sironi, J., Aranda, E., Nordstrøm, L. U., & Schwartz, E. L. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.113118 · Cited by 29
Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer
Kim, B. S., Clinton, J., Wang, Q., & Chang, S. H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1682380 · Cited by 29
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
Remón, J., Besse, B., Leary, A. F., Bièche, I., Job, B., Lacroix, L., Auguste, A., Mauduit, M., Audigier-Valette, C., Raimbourg, J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100068 · Cited by 28
Koopman, B., Groen, H. J. M., Schuuring, E. M. D., Hiltermann, T. J. N., Timens, W., den Dunnen, W. F. A., van den Berg, A., ter Elst, A., van Kruchten, M., Kluiver, J. L., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.06.011 · Cited by 29
Wu, Y., Ni, H., Yang, D., Niu, Y., Chen, K., Xu, J., Wang, F., Tang, S., Shi, Y., Zhang, H., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153551 · Cited by 29
Li, T., Wang, H., Xu, J., Li, C., Zhang, Y., Wang, G., Liu, Y., Cai, S., Fang, W., Li, J., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211038477 · Cited by 29
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022) · Cancers · doi:10.3390/cancers14112613 · Cited by 32
Hou, H., Zhang, C., Qi, X., Zhou, L., Liu, D., Lv, H., Li, T., Sun, D., & Zhang, X. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1665392 · Cited by 28
Lewis, W. E., Hong, L., Mott, F. E., Simon, G. R., Wu, C. C., Rinsurongkawong, W., Lee, J. J., Lam, V. K. L., Heymach, J. V., Zhang, J. J., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100237 · Cited by 28
Testa, U., Pelosi, E., & Castelli, G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017774 · Cited by 28
Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
Seo, D., & Lim, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115917 · Cited by 28
Precision oncology: current and future platforms for treatment selection
Tang, X., Berger, M. F., & Solit, D. B. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.009 · Cited by 32
Self-citationFinding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Gao, Y., Vallentgoed, W., & French, P. J. (2018) · Cancers · doi:10.3390/cancers10120489 · Cited by 26
Barquín, M., Calvo, V., Garcia‐García, F., Núñez, B., Sánchez‐Herrero, E., Serna‐Blasco, R., Auglytė, M., Carcereny, E., Rodríguez‐Abreu, D., Castro, R. L., et al. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101737 · Cited by 27
Rapid EGFR Mutation Detection Using the Idylla Platform
Boroujeni, A. M., Salazar, P. A., Zheng, T., Mensah, N. Y., Rijo, I., Doğan, S., Yao, J., Moung, C., Vanderbilt, C., Benhamida, J. K., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.11.009 · Cited by 27
Self-citationMurciano‐Goroff, Y. R., Pak, T., Mondaca, S., Flynn, J. R., Montecalvo, J., Rekhtman, N., Halpenny, D. F., Plodkowski, A. J., Wu, S. L., Kris, M. G., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01679-1 · Cited by 27
Self-citationAnticancer activity of 2’-hydroxyflavanone towards lung cancer
Awasthi, S., Singhal, S. S., Singhal, J., Nagaprashantha, L. D., Li, H., Yuan, Y., Liu, Z., Berz, D., Igid, H. P., Green, W. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26329 · Cited by 26
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy DevelopmentPreprint
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
O′Flaherty, L., Shnyder, S. D., Cooper, P. A., Cross, S., Wakefield, J. G., Pardo, O. E., Seckl, M. J., & Tavaré, J. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214610 · Cited by 25
Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis
Xie, Z., Li, X., Lun, Y., He, Y., Wu, S., Wang, S., Sun, J., He, Y., Xin, S., & Zhang, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107090 · Cited by 25
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges
Servetto, A., Esposito, D., Ferrara, R., Signorelli, D., Belli, S., Napolitano, F., Santaniello, A., Ciciola, P., Formisano, L., & Bianco, R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188810 · Cited by 25
Yang, C., Liao, W., Ho, C., Chen, K., Tsai, T.-H., Hsu, C., Liu, Y., Su, K., Chang, Y., Wu, C., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0088 · Cited by 25
Watanabe, S., Furuya, N., Nakamura, A., Shiihara, J., Nakachi, I., Tanaka, H., Nakao, M., Minato, K., Seike, M., Sasaki, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113469 · Cited by 26
Tomlins, S. A., Hovelson, D. H., Harms, P. W., Drewery, S., Falkner, J. A., Fischer, A. K., Hipp, J., Kwiatkowski, K., de la Vega, L. L., Mitchell, K., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.08.005 · Cited by 24
Li, S., Zhu, S., Wei, H., Zhu, P., Jiao, Y., Yi, M., Gong, J., Zheng, K., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113959 · Cited by 26
TFAP2A activates HMGA1 to promote glycolysis and lung adenocarcinoma progression
Zhao, J., & Lan, G. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154759 · Cited by 24
Ernst, S. M., van Marion, R., Atmodimedjo, P. N., de Jonge, E., Mathijssen, R. H. J., Paats, M. S., de Bruijn, P., Koolen, S. L., von der Thüsen, J. H., Aerts, J. G. J. V., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.04.007 · Cited by 24
Lung Cancer with a High Tumor Mutational Burden
VanderLaan, P. A., Rangachari, D., & Costa, D. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1808566 · Cited by 24
Wei, Y., Wang, L., Zheng, J., Jia, Q., Brčić, L., Akaba, T., & Chu, Q. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-127 · Cited by 23
Novel molecular targets for the treatment of lung cancer
Rosell, R., Karachaliou, N., & Arrieta, O. G. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000590 · Cited by 24
Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature
Kettle, J. G., & Cassar, D. J. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1709443 · Cited by 23
Solomon, J. P., Yang, S., Choudhury, N. J., Ptashkin, R. N., Eslamdoost, N., Falcon, C. J., Martin, A. S., Plodkowski, A. J., Wilhelm, C., Shen, R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1321 · Cited by 23
Self-citationZhang, B., Wang, S., Qian, J., Yang, W., Qian, F., Lü, J., Zhang, Y., Qiao, R., & Han, B. (2018) · Cancer · doi:10.1002/cncr.31329 · Cited by 26
Gill, R. R., Murphy, D. J., Kravets, S., Sholl, L. M., Janne, P. A., & Johnson, B. E. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25241 · Cited by 23
Biological bases of cancer immunotherapy
Carazas, M. M. G., Pinto, J. A., & Casado, F. L. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.5 · Cited by 23
Huang, Y.-H., Tseng, J., Hsu, K.-H., Chen, K., Su, K., Yu, S., Chen, J. J. W., Yang, T., & Chang, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-91657-7 · Cited by 22
High GNG4 expression is associated with poor prognosis in patients with lung adenocarcinoma
Zhou, B., Zhu, W., Yuan, S., Wang, Y., Zhang, Q., Zheng, H., Zhu, L., & Xu, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14265 · Cited by 22
Zhu, F., & Ren, Z. (2022) · Oncology Reports · doi:10.3892/or.2022.8326 · Cited by 22
Yang, C.-Y., Yeh, Y., Wang, L., Lin, Y., Lin, S., Wang, S., Chu, P.-Y., Liu, Z.-Y., Su, Y., Ho, H., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100047 · Cited by 23
Oxidative Stress in Antigen Processing and Presentation
Chang, Q., Zhang, Y., Liu, X., Miao, P., Pu, W., Liu, S., Zhang, J., Yuan, T., Shen, G., & Xie, N. (2025) · MedComm – Oncology · doi:10.1002/mog2.70020 · Cited by 21
Dy, G. K., Nesline, M., Papanicolau‐Sengos, A., DePietro, P., LeVea, C., Early, A., Chen, H., Grand’Maison, A., Boland, P. M., Ernstoff, M. S., et al. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0743-x · Cited by 21
Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR
Williamson, D. F. K., Marris, S. R. N., Rojas‐Rudilla, V., Bruce, J. L., Paweletz, C. P., Oxnard, G. R., Sholl, L. M., & Dong, F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264201 · Cited by 21
Fujiwara, Y., Makihara, R. A., Hase, T., Hashimoto, N., Naito, T., Tsubata, Y., Okuno, T., Takahashi, T., Kobayashi, H., Shinno, Y., et al. (2023) · Cancer Science · doi:10.1111/cas.15736 · Cited by 20
Elkrief, A., Odintsov, I., Markov, V., Caeser, R., Sobczuk, P., Tischfield, S. E., Bhanot, U. K., Vanderbilt, C., Cheng, E. H., Drilon, A. E. D. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.007 · Cited by 23
Self-citationTargeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 24
Lee, S., Lee, B., Shim, J., Lee, K. W., Yun, J. W., Kim, S.-Y., Kim, T., Kim, Y. H., Ko, Y. H., Chung, H. C., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.132 · Cited by 21
Self-citationWaterhouse, D. M., Rothschild, S. I., Dooms, C., Mennecier, B., Bozorgmehr, F., Majem, M., van den Heuvel, M. H., Linardou, H., Cho, B. C., Roberts‐Thomson, R., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107921 · Cited by 22
Chen, M., Huang, Y., Jiang, S., & Ke, C. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107966 · Cited by 21
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Zhao, Y., Wang, S., Yang, Z., Dong, Y., Wang, Y., Zhang, L., Hu, H., & Han, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665484 · Cited by 20
Lei, Y., Wang, K., Liu, Y., Wang, X., Xiang, X., Ning, X., Ding, W., Duan, J., Li, D., Wei, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811601 · Cited by 20
Bourreau, C., Treps, L., Faure, S., Fradin, D., & Clere, N. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108347 · Cited by 20
Kinoshita, K., Morikawa, K., Tsuruoka, H., Chosokabe, M., Kida, H., Handa, H., Inoue, T., Miyazawa, T., Saji, H., & Mineshita, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-29007-y · Cited by 20
Chamorro, D. F., Cardona, A. F., Rodríguez, J. K., Ruíz-Patiño, A., Arrieta, O. G., Pérez, D. A. M., Rojas, L., Zatarain-Barrón, Z. L., Ardila, D. V., Viola, L., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00955-9 · Cited by 21
Engineering Heterogeneous Tumor Models for Biomedical Applications
Wu, Z., Huang, D., Wang, J., Zhao, Y., Sun, W., & Shen, X. (2023) · Advanced Science · doi:10.1002/advs.202304160 · Cited by 19
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy
Nuryadi, E., Sasaki, Y., Hagiwara, Y., Permata, T. B. M., Sato, H., Komatsu, S., Yoshimoto, Y., Murata, K., Ando, K., Kubo, N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25982 · Cited by 20
Acquired Resistance in Lung Cancer
Tulpule, A., & Bivona, T. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033502 · Cited by 21
Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?
Makarem, M., & Leighl, N. B. (2020) · Cancer · doi:10.1002/cncr.32875 · Cited by 20
Prospective Clinical Sequencing of Adult Glioma
Zheng, S., Alfaro-Munoz, K. D., Wei, W., Wang, X., Wang, F., Eterovic, A. K., Shaw, K. R. M., Meric‐Bernstam, F., Fuller, G. N., Chen, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1122 · Cited by 20
Patient removals from general practitioner lists in Northern Ireland: 1987-1996.
O’Reilly, D., Steele, K., Merriman, B., Gilliland, A. E., & Brown, S. (1998) · Europe PMC (PubMed Central) · Cited by 20
The genomic landscape of lung cancer in never-smokers from the Women’s Health Initiative
Moorthi, S., Paguirigan, A. L., Itagi, P., Ko, M., Pettinger, M. B., Hoge, A. C. H., Nag, A., Patel, N. A., Wu, F., Sather, C. L., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.174643 · Cited by 21
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities
Zhang, J., Zeng, X., Guo, Q., Sheng, Z., Chen, Y., Wan, S., Zhang, L., & Zhang, P. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00548-w · Cited by 21
Molecular Pathology of Lung Cancer
Roy‐Chowdhuri, S. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.002 · Cited by 20
Vaclová, T., Chakraborty, A., Sherwood, J. L., Ross, S. J., Carroll, D. K., Barrett, J. C., Downward, J., & de Bruin, E. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06369-3 · Cited by 20
Yang, Y., Shen, S., Sun, Y., Husain, H., Zhou, H., Lü, S., & Li, Z. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-88 · Cited by 18
Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer
Nicoś, M., & Krawczyk, P. A. (2022) · Cancers · doi:10.3390/cancers14071813 · Cited by 21
Dhakar, R., Dakal, T. C., & Sharma, A. (2022) · Genomics · doi:10.1016/j.ygeno.2022.110401 · Cited by 19
Wankhede, D., Bontoux, C., Grover, S., & Hofman, P. M. (2023) · Diagnostics · doi:10.3390/diagnostics13193043 · Cited by 19
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction
Vaccaro, K., Allen, J., Whitfield, T. W., Maoz, A., Reeves, S., Velarde, J., Yang, D., Meglan, A., Ribeiro, J., Blandin, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169315 · Cited by 19
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 22
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20
Self-citationPark, E., & Shim, H. S. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.305 · Cited by 20
Basket trials: From tumour gnostic to tumour agnostic drug development
Dittrich, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102082 · Cited by 18
Blons, H., Oudart, J.-B., Merlio, J., Debieuvre, D., de Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P., Fraboulet, S. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.008 · Cited by 19
Kim, J. H., Yoon, S., Lee, K. H., Jang, S. J., Chun, S., & Kim, S. (2021) · Cancer Medicine · doi:10.1002/cam4.3874 · Cited by 19
Rocca, A., Crinò, L., Braga, L., Salton, F., Ruaro, B., Confalonieri, M., Generali, D., & Confalonieri, P. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03139-6 · Cited by 24
Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
Volckmar, A., Christopoulos, P., Kirchner, M., Allgäuer, M., Neumann, O., Budczies, J., Rempel, E., Horak, P., Glade, J., Goldschmid, H., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.022 · Cited by 18
Riudavets, M., Naigeon, M., Texier, M., Dorta, M., Barlési, F., Mazières, J., Varga, A., Cassard, L., Boselli, L., Grivel, J., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.018 · Cited by 19
Zhang, H., Cao, Y., Tang, J., & Wang, R. (2022) · BioMed Research International · doi:10.1155/2022/9944847 · Cited by 18
RetractedDSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity
Valencia, K., Echepare, M., Teijeira, Á., Pasquier, A., Bértolo, C., Sainz, C., Tamayo, I., Picabea, B., Bosco, G., Thomas, R. K., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220726 · Cited by 19
Li, Q., Zhou, Q., Zhao, S., Wu, P., Shi, P., Zeng, J., Xiong, X., Chen, H., Kittaneh, M., Bravaccini, S., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-655 · Cited by 18
Levis, M., Gastino, A., Giorgi, G. D., Mantovani, C., Bironzo, P., Mangherini, L., Ricci, A. A., Ricardi, U., Cassoni, P., & Bertero, L. (2023) · Cancers · doi:10.3390/cancers15184622 · Cited by 19
Zhang, B., Ma, Z., Tan, B., & Lin, N. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559824 · Cited by 18
FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium
Best, S. A., Harapas, C. R., Kersbergen, A. J., Rathi, V., Asselin-Labat, M.-L., & Sutherland, K. D. (2018) · Oncogene · doi:10.1038/s41388-018-0399-5 · Cited by 17
Chu, Y., Barbee, J., Yang, S., Chang, J. C., Liang, P., Mullaney, K. A., Chan, R., Salazar, P. A., Benayed, R., Offin, M. D., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.03.006 · Cited by 17
Self-citationXuzhang, W., Huang, H., Yu, Y., Shen, L., Li, Z., & Lü, S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231156387 · Cited by 17
Hofman, V., Benzaquen, J., Heeke, S., Lassalle, S., Poudenx, M., Long-Mira, É., Lantéri, E., Bordone, O., Lespinet‐Fabre, V., Tanga, V., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.024 · Cited by 17
The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
Crombet, T., Morales, O. S., Dy, G. K., León, K., & Dávila, A. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639745 · Cited by 18
Desmeules, P., Boudreau, D. K., Bastien, N., Boulanger, M., Bossé, Y., Joubert, P., & Couture, C. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100276 · Cited by 17
Shimizu, Y., Okada, K., Adachi, J., Abe, Y., Narumi, R., Uchibori, K., Yanagitani, N., Koike, S., Takagi, S., Nishio, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00260-0 · Cited by 16
Fregni, M., Ciribilli, Y., & Zawacka‐Pankau, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137213 · Cited by 16
Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer
Kirk, N. A., Kim, K., & Park, K.-S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00905-x · Cited by 17
Schenk, E. L. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-883 · Cited by 18
Miura, K., Shukuya, T., Greenstein, R., Kaplan, B., Wakelee, H. A., Kurokawa, K., Furuta, K., Kato, S., Suh, J., Sivakumar, S., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7021 · Cited by 17
Hellmann, M. D., Hayashi, T., Reva, B. A., Yu, H. A., Riely, G. J., Adusumilli, P. S., Travis, W. D., Wilkins, O., Bramletta, N., Chandramohan, R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00019 · Cited by 17
Self-citationTsukumo, Y., Naito, M., & Suzuki, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229712 · Cited by 18
Jiang, J., Adams, H.-P., Lange, M. G., Siemann, S., Feldkamp, M., McNamara, S., Froehler, S., Yaung, S. J., Yao, L., Balasubramanyam, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07340-z · Cited by 16
Xiang, L., Fu, X., Wang, X., Li, W., Zheng, X., Nan, K., & Tian, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.559896 · Cited by 16
Carlo, E. D., Bertoli, E., Conte, A. D., Stanzione, B., Berto, E., Revelant, A., Spina, M., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126477 · Cited by 15
Metadata
- Authors
- Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., Jayakumaran, G., Gao, S. P., Johnsen, H. C., Hanrahan, A. J., Zehir, A., Rekhtman, N., Ginsberg, M. S., Li, B. T., Yu, H. A., Paik, P. K., Drilon, A., Hellmann, M. D., Reales, D. N., Benayed, R., Rusch, V. W., Kris, M. G., Chaft, J. E., Baselga, J., Taylor, B. S., Schultz, N., Rudin, C. M., Hyman, D. M., Berger, M. F., Solit, D. B., Ladanyi, M., & Riely, G. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Riely, Gregory J.
- ORCID
- Jordan, Emmet J.
- Kim, Hyunjae R.
- Arcila, Maria E.
- Chakravarty, Debyani
- Gao, JianJiong
- Kundra, Ritika
- Jonsson, Philip
- Jayakumaran, Gowtham
- Zehir, Ahmet
- Rekhtman, Natasha
- Ginsberg, Michelle S.
- Li, Bob T.
- Yu, Helena A.
- Paik, Paul K.
- Drilon, Alexander
- Hellmann, Matthew D.
- Reales, Dalicia N.
- Benayed, Ryma
- Rusch, Valerie W.
- Kris, Mark G.
- Chaft, Jamie E.
- Taylor, Barry S.
- Schultz, Nikolaus
- Rudin, Charles M.
- Hyman, David M.
- Berger, Michael F.
- Solit, David B.
- Ladanyi, Marc
- Riely, Gregory J.
- Venue
- Cancer Discovery
- Published
- 2017-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 596-609
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5482929
- OpenAlex
- W2603411876
- Cited by
- 643
- References
- 49
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 65 · 2023: 99 · 2022: 94 · 2021: 101 · 2020: 79 · 2019: 65 · 2018: 55 · 2017: 12
- FWCI
- 47.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Cancer Institute (P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, metastatic lung cancer, actionable mutations, targeted therapy, predictive biomarkers, drug response, STK11, Keap1, clinical benefit, molecular profiling
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Adolescent, Adult, Aged, Female, Genetic Testing, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Biomarkers, Tumor, Young Adult, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
